QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
QQQ   444.71 (-0.03%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NYSE:ELAN

Elanco Animal Health (ELAN) Stock Price, News & Analysis

$16.22
+0.05 (+0.31%)
(As of 12:03 PM ET)
Today's Range
$16.12
$16.30
50-Day Range
$14.54
$16.47
52-Week Range
$7.88
$16.88
Volume
465,225 shs
Average Volume
4.38 million shs
Market Capitalization
$8.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.71

Elanco Animal Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
3.3% Upside
$16.71 Price Target
Short Interest
Healthy
2.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-4.69
Upright™ Environmental Score
News Sentiment
1.35mentions of Elanco Animal Health in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$322,800 Bought Last Quarter
Proj. Earnings Growth
15.38%
From $0.91 to $1.05 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.40 out of 5 stars

Medical Sector

284th out of 939 stocks

Pharmaceutical Preparations Industry

126th out of 434 stocks

ELAN stock logo

About Elanco Animal Health Stock (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN Stock Price History

ELAN Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Breaking Down Elanco Animal Health: 6 Analysts Share Their Views
Q4 2023 Elanco Animal Health Inc Earnings Call
Elanco Q4 2023 Earnings Preview
Elanco to Participate in Upcoming Investor Conferences
Elanco Animal Health: A Solid Sale Addresses Leverage
See More Headlines
Receive ELAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
9,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.71
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+3.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-1,231,000,000.00
Pretax Margin
-27.06%

Debt

Sales & Book Value

Annual Sales
$4.42 billion
Cash Flow
$2.34 per share
Book Value
$12.63 per share

Miscellaneous

Free Float
461,420,000
Market Cap
$7.98 billion
Optionable
Optionable
Beta
1.29
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


ELAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Elanco Animal Health stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ELAN shares.
View ELAN analyst ratings
or view top-rated stocks.

What is Elanco Animal Health's stock price target for 2024?

7 brokers have issued 1-year price objectives for Elanco Animal Health's stock. Their ELAN share price targets range from $12.00 to $20.00. On average, they anticipate the company's stock price to reach $16.71 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price.
View analysts price targets for ELAN
or view top-rated stocks among Wall Street analysts.

How have ELAN shares performed in 2024?

Elanco Animal Health's stock was trading at $14.90 at the beginning of the year. Since then, ELAN stock has increased by 8.6% and is now trading at $16.18.
View the best growth stocks for 2024 here
.

Are investors shorting Elanco Animal Health?

Elanco Animal Health saw a decline in short interest in March. As of March 15th, there was short interest totaling 12,980,000 shares, a decline of 5.2% from the February 29th total of 13,690,000 shares. Based on an average daily trading volume, of 4,340,000 shares, the days-to-cover ratio is presently 3.0 days.
View Elanco Animal Health's Short Interest
.

When is Elanco Animal Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ELAN earnings forecast
.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) released its quarterly earnings data on Monday, February, 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by $0.02. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive trailing twelve-month return on equity of 6.44%. The firm's revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company earned $0.19 earnings per share.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.870-0.950 for the period, compared to the consensus EPS estimate of 0.890. The company issued revenue guidance of $4.5 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Jeff Simmons' approval rating as Elanco Animal Health's CEO?

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

When did Elanco Animal Health IPO?

Elanco Animal Health (ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dodge & Cox (17.04%), Primecap Management Co. CA (10.27%), Vanguard Group Inc. (10.04%), Vanguard Group Inc. (10.03%), Price T Rowe Associates Inc. MD (4.32%) and Dimensional Fund Advisors LP (3.06%). Insiders that own company stock include Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends
.

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ELAN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners